The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
Open accessAbstract
SUMMARY Overcoming immune-mediated resistance to PD1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD1) and relatlimab (anti-LAG3) treatment, the first in its class to be FDA-approved. However, how these two inhibitory receptors synergize to hinder anti-tumor immunity remains unknown. Here, we show that PD1/LAG3-deficient CD8+ T cells, in contrast to CD8+ T cells lacking either receptor, mediate enhanced tumor clearance and long-term survival in mouse models of melanoma. PD1/LAG3-deficient CD8+ T cells were transcriptionally distinct, with broad TCR clonality and enrichment of effector-like and interferon-responsive genes, resulting in enhanced IFNγ release indicative of functionality. LAG3 and PD1 combined to drive T cell exhaustion, playing a dominant role in modulating TOX expression. Mechanistically, autocrine, cell-intrinsic IFNγ signaling was required for PD1/LAG3-deficient CD8+ T cells to enhance anti-tumor immunity, providing insight into how combinatorial targeting of LAG3 and PD1 enhances efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationLa Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K., Kastriti, M. E., Lönnerberg, P., Furlan, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0414-6 · Cited by 4,118
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Fast gene set enrichment analysis
Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M. N., & Sergushichev, A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/060012 · Cited by 3,454
Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors
Haghverdi, L., Lun, A. T. L., Morgan, M. D., & Marioni, J. C. (2018) · Nature Biotechnology · doi:10.1038/nbt.4091 · Cited by 2,416
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Self-citationBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Self-citationCD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Self-citationRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
McCarthy, D. J., Campbell, K. R., Lun, A. T. L., & Wills, Q. F. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw777 · Cited by 1,852
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Self-citationTOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646
Self-citationA step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor
Lun, A. T. L., McCarthy, D. J., & Marioni, J. C. (2016) · F1000Research · doi:10.12688/f1000research.9501.2 · Cited by 1,574
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
TOX is a critical regulator of tumour-specific T cell differentiation
Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106
Beltra, J.-C., Manne, S., Abdel-Hakeem, M. S., Kurachi, M., Giles, J. R., Chen, Z., Casella, V., Ngiow, S. F., Khan, O., Huang, Y. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.014 · Cited by 1,082
Self-citationRescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Self-citationLAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
Self-citationOrchestrating single-cell analysis with Bioconductor
Amezquita, R. A., Lun, A. T. L., Becht, E., Carey, V. J., Carpp, L. N., Geistlinger, L., Marini, F., Rue-Albrecht, K., Risso, D., Soneson, C., et al. (2020) · Nature Methods · doi:10.1038/s41592-019-0654-x · Cited by 945
Differential abundance testing on single-cell data using k-nearest neighbor graphs
Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D., & Marioni, J. C. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01033-z · Cited by 938
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 899
TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision
Chen, Z., Ji, Z., Ngiow, S. F., Manne, S., Cai, Z., Huang, A. C., Johnson, J., Staupe, R. P., Bengsch, B., Xu, C., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.013 · Cited by 709
RANTES: a versatile and controversial chemokine
Appay, V., & Rowland-Jones, S. L. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01812-3 · Cited by 650
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Self-citationNeoadjuvant relatlimab and nivolumab in resectable melanoma
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., Glitza, I. C., Duan, F., Milton, D. R., Busam, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05368-8 · Cited by 345
TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data
Song, L., Cohen, D., Ouyang, Z., Cao, Y., Hu, X., & Liu, X. S. (2021) · Nature Methods · doi:10.1038/s41592-021-01142-2 · Cited by 337
Giles, J. R., Ngiow, S. F., Manne, S., Baxter, A. E., Khan, O., Wang, P., Staupe, R., Abdel-Hakeem, M. S., Huang, H., Mathew, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01338-4 · Cited by 264
Self-citationHuang, R., Wang, S., Wang, N., Zheng, Y., Zhou, J., Yang, B., Wang, X., Zhang, J., Guo, L., Wang, S., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2435-y · Cited by 263
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 258
Self-citationGuy, C., Mitrea, D. M., Chou, P.-C., Temirov, J., Vignali, K. M., Liu, X., Zhang, H., Kriwacki, R., Bruchez, M. P., Watkins, S. C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01176-4 · Cited by 213
Self-citationarcasHLA: high-resolution HLA typing from RNAseq
Orenbuch, R., Filip, I., Comito, D., Shaman, J., Pe’er, I., & Rabadan, R. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz474 · Cited by 201
Valpione, S., Mundra, P. A., Galvani, E., Campana, L. G., Lorigan, P., De Rosa, F., Gupta, A., Weightman, J., Mills, S., Dhomen, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24343-x · Cited by 194
A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral Infection
Crawford, A., Angelosanto, J. M., Nadwodny, K. L., Blackburn, S. D., & Wherry, E. J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002098 · Cited by 190
Self-citationbabelgene: Gene Orthologs for Model Organisms in a Tidy Data Format
Dolgalev, I. (2021) · CRAN: Contributed Packages · doi:10.32614/cran.package.babelgene · Cited by 184
Cillo, A. R., Cardello, C., Shan, F., Karapetyan, L., Kunning, S., Sander, C., Rush, E., Karunamurthy, A., Massa, R. C., Rohatgi, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.036 · Cited by 180
Self-citationPresto scales Wilcoxon and auROC analyses to millions of observationsPreprint
Korsunsky, I., Nathan, A., Millard, N., & Raychaudhuri, S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/653253 · Cited by 175
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes
Zhang, Q., Chikina, M., Szymczak-Workman, A. L., Horne, W., Kolls, J. K., Vignali, K. M., Normolle, D., Bettini, M., Workman, C. J., & Vignali, D. A. A. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah4569 · Cited by 164
Self-citationAccurate and fast cell marker gene identification with COSG
Dai, M., Pei, X., & Wang, X.-J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab579 · Cited by 158
Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)
Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 138
Self-citationTCR Specificity Dictates CD94/NKG2A Expression by Human CTL
Jabri, B., Selby, J. M., Negulescu, H., Lee, L., Roberts, A. I., Beavis, A., Lopez-Botet, M., Ebert, E. C., & Winchester, R. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00427-2 · Cited by 136
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
Andrews, L. P., Cillo, A. R., Karapetyan, L., Kirkwood, J. M., Workman, C. J., & Vignali, D. A. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2390 · Cited by 133
Self-citationChen, R., Bélanger, S., Frederick, M. A., Li, B., Johnston, R. J., Xiao, N., Liu, Y., Sharma, S., Peters, B., Rao, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.002 · Cited by 126
Ngiow, S. F., Manne, S., Huang, Y., Azar, T., Chen, Z., Mathew, D., Chen, Q., Khan, O., Wu, J. E., Alcalde, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.018 · Cited by 123
Self-citationSingle-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
Pauken, K. E., Shahid, O., Lagattuta, K. A., Mahuron, K. M., Luber, J. M., Lowe, M. M., Huang, L., Delaney, C., Long, J. M., Fung, M. E., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200920 · Cited by 121
Self-citationHuuhtanen, J., Kasanen, H. H. E., Peltola, K. J., Lönnberg, T., Glumoff, V., Brück, O. E., Dufva, O., Peltonen, K., Vikkula, J., Jokinen, E., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164809 · Cited by 105
Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function
Kurachi, M., Kurachi, J., Chen, Z., Johnson, J. L., Khan, O., Bengsch, B., Stelekati, E., Attanasio, J., McLane, L. M., Tomura, M., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2017.083 · Cited by 78
Self-citationDerré, L., Corvaisier, M., Pandolfino, M., Diez, E., Jotereau, F., & Gervois, N. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4864 · Cited by 65
Expression of CD94–NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells
Braud, V. M., Aldemir, H., Bréart, B., & Ferlin, W. G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00064-4 · Cited by 65
Distinct requirement of Runx complexes for TCRβ enhancer activation at distinct developmental stages
Seo, W., Muroi, S., Akiyama, K., et al. (2017) · Scientific Reports · doi:10.1038/srep41351 · Cited by 23
IL-27 Induces CCL5 Production by T Lymphocytes, Which Contributes to Antitumor Activity
Hu, A., Zhu, J., Zeng, C., Lin, C.-H., Yu, J., Liu, J.-Q., Lynch, K., Talebian, F., Pan, X. J., Yan, J., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100885 · Cited by 14
Metadata
- Authors
- Andrews, L. P., Butler, S. C., Cui, J., Cillo, A. R., Cardello, C., Liu, C., Brunazzi, E. A., Baessler, A., Xie, B., Kunning, S. R., Ngiow, S. F., Huang, Y. J., Manne, S., Sharpe, A. H., Delgoffe, G. M., Wherry, E. J., Kirkwood, J. M., Bruno, T. C., Workman, C. J., & Vignali, D. A. A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 187
- Issue
- 16
- Pages
- 4355-4372.e22
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4401420347
- Cited by
- 279
- References
- 60
- FWCI
- 42.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.